GlassScriptPhysician profile
Sholeh Rahimi
NPI 1427183003
$2,068.91
in general payments reported to CMS, 2019-2025
21 companies · $820 in 2025
The $820 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.63 · 2021: $31.23 · 2022: $220 · 2023: $463 · 2024: $500 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.48 | 2022-2025 | |
| Exact Sciences Corporation | $262.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $164.62 | 2023-2025 | |
| Novo Nordisk INC | $157.00 | 2022-2025 | Wegovy, Ozempic, Saxenda |
| Merck Sharp & Dohme LLC | $151.17 | 2022-2024 | Dificid |
| Xeris Pharmaceuticals, INC. | $139.65 | 2022-2023 | Keveyis |
| Lilly USA, LLC | $136.44 | 2025 | Zepbound, Kisunla |
| Amgen INC. | $82.77 | 2022-2023 | Prolia, Evenity |
| Kowa Pharmaceuticals America, INC. | $79.96 | 2022-2025 | Zoryve, Seglentis |
| Astrazeneca Pharmaceuticals LP | $68.83 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.29 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $55.80 | 2025 | Korlym |
| Orapharma, A Division of Bausch Health US, LLC | $54.72 | 2024-2025 | Arestin |
| Idorsia Pharmaceuticals US INC | $42.33 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $35.81 | 2024 | Aplenzin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.36 | 2023-2024 | Eliquis |
| Eisai INC. | $31.23 | 2021 | |
| Glaxosmithkline, LLC. | $23.85 | 2023 | Shingrix, Arexvy |
| Rgh Enterprises LLC | $20.61 | 2024 | |
| Scilex Pharmaceuticals INC. | $20.04 | 2025 | |
| Henry Schein, INC. | $16.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sholeh Rahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.